Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study

Palisade Bio, a biopharmaceutical company focused on gastrointestinal complications, has announced the completion of patient enrollment in its LB1148 dose optimization study. The study aims to generate valuable data on pharmacokinetics and pharmacodynamics across multiple doses in healthy adult volunteers. This milestone brings Palisade Bio closer to obtaining Phase 2 topline data for the preven..

• format_list_bulleted BS
• · 2023. 7. 6.
• textsms

Auxilius Pharma Raises Seed Round of $1 Million and Commences its Clinical Program

Auxilius Pharma has raised $1 million in seed funding to develop its lead asset, AUX-001, a new medication for treating chronic-stable angina pectoris in the US. The company is developing the drug as there have been very few medications developed to address chest pain symptoms suffered by patients with underlying coronary artery disease. Auxilius plans to conduct a first-in-human exploratory pha..

• format_list_bulleted BS
• · 2023. 6. 20.
• textsms